
The USA-based non-profit Institute for Patient Access (IfPA) has released the results of a recent poll of physicians showing concern about the federal government’s 340B drug pricing program, which was designed to encourage care for indigent and underinsured patients but has instead ballooned into a revenue stream for growing hospital systems.
The IfPA's research was released in advance of Tuesday's hearing by the Senate Health, Education, Labor and Pensions Committee to examine oversight reports on the 340B program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze